{"id":"epoetin-beta-pegol","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Thrombotic events (venous thromboembolism)"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Pure red cell aplasia"}]},"_chembl":{"chemblId":"CHEMBL2109092","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This drug is a long-acting formulation of erythropoietin created by attaching polyethylene glycol (PEG) chains to epoetin beta, which extends its half-life and reduces dosing frequency. It mimics the natural hormone erythropoietin to promote red blood cell production in patients with anemia, particularly those with chronic kidney disease or cancer-related anemia. The pegylation allows for less frequent subcutaneous or intravenous administration compared to conventional epoetin formulations.","oneSentence":"Epoetin beta pegol is a pegylated erythropoietin analog that stimulates erythropoiesis by binding to and activating the erythropoietin receptor on bone marrow progenitor cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:46:18.922Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Anemia in patients with chronic kidney disease"},{"name":"Anemia in patients with cancer receiving chemotherapy"}]},"trialDetails":[{"nctId":"NCT06520826","phase":"PHASE3","title":"Vafseo Outcomes In-Center Experience","status":"ACTIVE_NOT_RECRUITING","sponsor":"USRC Kidney Research","startDate":"2024-11-20","conditions":"Anemia of Chronic Kidney Disease","enrollment":2200},{"nctId":"NCT00661388","phase":"PHASE3","title":"A Study of Monthly Subcutaneous Mircera for the Treatment of Chronic Renal Anemia in Predialysis Patients Not Treated With ESA.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-08","conditions":"Anemia","enrollment":75},{"nctId":"NCT00560404","phase":"PHASE3","title":"A Study of Subcutaneous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-04","conditions":"Anemia","enrollment":233},{"nctId":"NCT02567188","phase":"","title":"A Study of MIRCERA in Participants With Chronic Kidney Disease Stage 3-4 and Not on Dialysis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-04","conditions":"Anemia","enrollment":144},{"nctId":"NCT07119372","phase":"PHASE3","title":"Study of the Efficacy and Safety of BCD-131 and Mircera® in the Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis","status":"RECRUITING","sponsor":"Biocad","startDate":"2025-03-01","conditions":"Anemia, Chronic Kidney Disease, Chronic Kidney Disease Patients on Hemodialysis","enrollment":228},{"nctId":"NCT04707768","phase":"PHASE3","title":"Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects","status":"COMPLETED","sponsor":"Akebia Therapeutics","startDate":"2021-06-18","conditions":"Anemia Associated With Chronic Kidney Disease (CKD)","enrollment":456},{"nctId":"NCT02988973","phase":"PHASE3","title":"A Study of Intermittent Oral Dosing of ASP1517 in Non-Dialysis Chronic Kidney Disease Patients With Anemia","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2017-01-12","conditions":"Chronic Kidney Disease","enrollment":334},{"nctId":"NCT05265325","phase":"PHASE2","title":"A Study of AND017 to Treat Anemia in Chronic Kidney Disease Patients on Dialysis","status":"COMPLETED","sponsor":"Kind Pharmaceuticals LLC","startDate":"2023-05-03","conditions":"Renal Anemia","enrollment":175},{"nctId":"NCT05951192","phase":"PHASE4","title":"A Prospective Interventional Study Assessing the Clinical and Operational Effectiveness of Transitioning From Mircera to Daprodustat for the Treatment of Anemia in End Stage Kidney Disease","status":"COMPLETED","sponsor":"USRC Kidney Research","startDate":"2023-07-01","conditions":"Anemia, Renal Insufficiency, Chronic, Renal Anemia","enrollment":161},{"nctId":"NCT04155125","phase":"PHASE3","title":"A Study of Efepoetin Alfa in Treating Anaemia Associated With Chronic Kidney Diseases Patient","status":"COMPLETED","sponsor":"PT Kalbe Genexine Biologics","startDate":"2020-07-02","conditions":"Anaemia Associated With Chronic Kidney Disease","enrollment":391},{"nctId":"NCT05719376","phase":"PHASE4","title":"The Effect of Intravenous Iron Therapy and Erythropoiesis-stimulation Agent Combination on Renal Transplant Outcomes","status":"NOT_YET_RECRUITING","sponsor":"Yonsei University","startDate":"2023-02","conditions":"Kidney Failure, Chronic","enrollment":302},{"nctId":"NCT04410198","phase":"PHASE3","title":"Study of Roxadustat Conversion in Participants Receiving Stable Erythropoiesis-Stimulating Agent (ESA) or as Initial Anemia Treatment in Chronic Dialysis Participants","status":"COMPLETED","sponsor":"Kyntra Bio","startDate":"2020-05-26","conditions":"Anemia Associated With End Stage Renal Disease (ESRD)","enrollment":203},{"nctId":"NCT04484857","phase":"PHASE3","title":"Study of Roxadustat Conversion in Participants Receiving Stable ESA or as Initial Anemia Treatment in Hemodialysis Participants","status":"COMPLETED","sponsor":"Kyntra Bio","startDate":"2020-07-22","conditions":"Anemia Associated With End Stage Renal Disease","enrollment":283},{"nctId":"NCT03552393","phase":"PHASE2","title":"Ascertain the Optimal Starting Dose of Mircera Given Subcutaneously for Maintenance Treatment of Anemia in Pediatric Patients With Chronic Kidney Disease on Dialysis or Not Yet on Dialysis.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2018-08-03","conditions":"Anemia, Renal Insufficiency, Chronic","enrollment":40},{"nctId":"NCT02832323","phase":"NA","title":"Interest of the Peak of Reticulocytes in Chronic Hemodialysis Patients Treated by Mircera Hemodialysis Population","status":"TERMINATED","sponsor":"University Hospital, Brest","startDate":"2016-06-22","conditions":"Renal Insufficiency, Chronic","enrollment":94},{"nctId":"NCT02273726","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis","status":"COMPLETED","sponsor":"Kyntra Bio","startDate":"2015-01-15","conditions":"CKD Anemia in Stable Dialysis Patients","enrollment":741},{"nctId":"NCT00642967","phase":"PHASE3","title":"A Study of Subcutaneous Mircera for the Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease Not on Dialysis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-06","conditions":"Anemia","enrollment":127},{"nctId":"NCT00717821","phase":"PHASE3","title":"A Study of Once Monthly Intravenous or Subcutaneous Mircera in Participants With Chronic Kidney Disease on Hemodialysis.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-08","conditions":"Anemia","enrollment":421},{"nctId":"NCT02791763","phase":"PHASE3","title":"Phase III Study of GSK1278863 in Japanese Non-dialysis (ND) and Peritoneal Dialysis (PD) Subjects With Renal Anemia","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-06-06","conditions":"Anaemia","enrollment":355},{"nctId":"NCT03519243","phase":"PHASE2","title":"Comparative Study of the Efficacy and Safety of BCD-131 and Mircera in Treatment of Anemia in CKD Patients on Dialysis","status":"COMPLETED","sponsor":"Biocad","startDate":"2017-10-24","conditions":"Anemia","enrollment":75},{"nctId":"NCT04360902","phase":"NA","title":"Assessment of an Anemia Model Predictive Controller for Anemia Management in Hemodialysis Patients","status":"UNKNOWN","sponsor":"Renal Research Institute","startDate":"2020-01-08","conditions":"End Stage Renal Disease, Renal Anemia, Chronic Kidney Diseases","enrollment":60},{"nctId":"NCT00773513","phase":"PHASE4","title":"A Study to Assess All-Cause Mortality and Cardiovascular Morbidity in Participants With Chronic Kidney Disease (CKD) on Dialysis and Those Not on Renal Replacement Therapy Receiving Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) or Reference Erythropoietin Stimulating Agents (ESAs)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-12-12","conditions":"Chronic Renal Anemia","enrollment":2825},{"nctId":"NCT01902628","phase":"","title":"OPTIMA: An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Participants With Chronic Kidney Disease Stages 3 and 4 Not on Dialysis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-07-15","conditions":"Anemia","enrollment":437},{"nctId":"NCT01756612","phase":"","title":"A Study to Assess Hemoglobin Level Depending on the Comorbidity Index in Chronic Kidney Disease (CKD) Participants Not in Dialysis Treated With Methoxy Polyethylene Glycol-Epoetin Beta (COMETE)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2012-11-21","conditions":"Renal Anemia of Chronic Kidney Disease","enrollment":551},{"nctId":"NCT02731469","phase":"PHASE1","title":"Study of Pharmacokinetics, Pharmacodynamics, Safety of BCD-131 Compared to Mircera and Aranesp in Healthy Volunteers","status":"COMPLETED","sponsor":"Biocad","startDate":"2016-06-15","conditions":"Reticulocyte Count","enrollment":45},{"nctId":"NCT01519947","phase":"PHASE4","title":"A Study of The Effect of Altitude on Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) Dose Requirements in Participants With Chronic Renal Anemia in Pre-Dialysis or Dialysis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2012-05-30","conditions":"Anemia, Kidney Disease, Chronic","enrollment":87},{"nctId":"NCT01817699","phase":"PHASE4","title":"Correcting Anemia and Native Vitamin D Supplementation in Kidney Transplant Recipients","status":"TERMINATED","sponsor":"CANDLE-KIT Trial Study Group","startDate":"2013-04","conditions":"Kidney Transplantation, Anemia, Vitamin D Deficiency","enrollment":161},{"nctId":"NCT03427801","phase":"","title":"Effect of Erythropoiesis-Stimulating Agent Therapy in Patients Receiving Palliative Care of Chronic Kidney Disease","status":"COMPLETED","sponsor":"Chinese University of Hong Kong","startDate":"2017-03-01","conditions":"Anemia of Chronic Kidney Disease","enrollment":78},{"nctId":"NCT01191983","phase":"PHASE4","title":"A Study of Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) for the Treatment of Chronic Renal Anemia in Participants With Diabetic Nephropathy","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-08-13","conditions":"Anemia","enrollment":102},{"nctId":"NCT00642304","phase":"PHASE3","title":"A Study of Subcutaneous C.E.R.A. for the Maintenance of Hemoglobin Levels in Participants With Chronic Renal Anemia Not on Dialysis.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-03-27","conditions":"Anemia","enrollment":20},{"nctId":"NCT00360347","phase":"PHASE1, PHASE2","title":"A Study of Mircera in Anemic Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2001-11-29","conditions":"Anemia","enrollment":""},{"nctId":"NCT00048048","phase":"PHASE2","title":"A Study of Mircera in Anemic Patients With Chronic Kidney Disease Not Yet on Dialysis.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2002-03","conditions":"Anemia","enrollment":65},{"nctId":"NCT00737464","phase":"PHASE4","title":"A Study of Once Monthly Intravenous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-08-26","conditions":"Anemia","enrollment":132},{"nctId":"NCT00661505","phase":"PHASE3","title":"A Study of Intravenous Mircera in Hemodialysis Patients With Chronic Renal Anemia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-05-14","conditions":"Anemia","enrollment":132},{"nctId":"NCT01066000","phase":"PHASE4","title":"A Study for Monthly Methoxy Polyethylene Glycol-Epoetin Beta Treatment in Patients With Chronic Renal Anaemia","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2009-10-31","conditions":"Anemia","enrollment":33},{"nctId":"NCT02044653","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of GX-E2 in the Anemic Patients Diagnosed With Chronic Kidney Disease (CKD)","status":"COMPLETED","sponsor":"Genexine, Inc.","startDate":"2014-04-15","conditions":"Anemia, Chronic Kidney Disease","enrollment":257},{"nctId":"NCT02049346","phase":"PHASE4","title":"Comparison Among Erythropoietin Stimulating Agents","status":"COMPLETED","sponsor":"Hamad Medical Corporation","startDate":"2012-03","conditions":"Anemia of End Stage Renal Disease","enrollment":327},{"nctId":"NCT00717366","phase":"PHASE2","title":"Study to Determine Optimum Intravenous Starting Dose of MIRCERA for Treatment of Pediatric Participants With Anemia and Chronic Kidney Disease on Hemodialysis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-07","conditions":"Renal Anemia","enrollment":64},{"nctId":"NCT00922116","phase":"PHASE4","title":"A Study of Once Monthly Subcutaneous Mircera in Patients With Chronic Renal Anemia Not on Dialysis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-04-30","conditions":"Anemia","enrollment":191},{"nctId":"NCT01379963","phase":"","title":"A Retrospective Observational Study of Hemoglobin Levels in Patients With Renal Anemia Treated With Mircera (Methoxy Polyethylene Glycol-Epoetin Beta)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-04-30","conditions":"Anemia, Kidney Disease, Chronic","enrollment":780},{"nctId":"NCT01417377","phase":"","title":"An Observational Study of Mircera (Methoxy Polyethylene Glycol-epoetin Beta) in Anemic Patients With Chronic Kidney Disease (NORM)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-05-31","conditions":"Anemia","enrollment":22},{"nctId":"NCT01342640","phase":"PHASE4","title":"A Study of Mircera (C.E.R.A.) in Patients With Pre-Dialysis Chronic Renal Anemia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-07-18","conditions":"Anemia","enrollment":70},{"nctId":"NCT01677767","phase":"","title":"An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Chronic Kidney Disease Patients on Dialysis With Renal Anemia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-04-30","conditions":"Anemia","enrollment":127},{"nctId":"NCT00642668","phase":"PHASE4","title":"A Study of Subcutaneous Mircera for the Maintenance Treatment of Participants With Chronic Renal Anemia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-06-30","conditions":"Anemia","enrollment":35},{"nctId":"NCT01318512","phase":"","title":"An Observational Study of Mircera (Methoxy Polyethylene Glycol-epoetin Beta) in Patients With Chronic Kidney Disease Not On Dialysis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-07-31","conditions":"Kidney Disease, Chronic","enrollment":340},{"nctId":"NCT01356589","phase":"","title":"A Study of MIRCERA for the Intrapetient Variability of Hemoglobin Levels in Patients With Chronic Renal Anemia (RIVAL)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-09-30","conditions":"Anemia","enrollment":1288},{"nctId":"NCT01940484","phase":"","title":"An Observational Study of Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) in Stage V Chronic Kidney Disease Participants on Hemodialysis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-08-31","conditions":"Anemia","enrollment":98},{"nctId":"NCT02596945","phase":"","title":"Observational Study of Methoxy Polyethylene Glycol Epoetin Beta Daily Use in Participants on Peritoneal Dialysis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-07-31","conditions":"Renal Impairment, Renal Anemia of Chronic Kidney Disease","enrollment":223},{"nctId":"NCT00737477","phase":"PHASE3","title":"A Study of Monthly Subcutaneous (SC) Mircera for Maintenance Treatment of Participants With Chronic Kidney Disease on Peritoneal Dialysis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-09-30","conditions":"Anemia","enrollment":96},{"nctId":"NCT02538107","phase":"","title":"An Observational Study of Methoxy Polyethylene Glycol-epoetin Beta in Participants With a Kidney Transplant","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-09-30","conditions":"Anemia, Kidney Transplantation","enrollment":290},{"nctId":"NCT02547454","phase":"","title":"An Observational Study to Evaluate the Effectiveness of Mircera Treatment for Renal Anemia in Pre-dialysis Participants With Chronic Kideny Disease (CKD)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-12-31","conditions":"Kidney Disease, Chronic","enrollment":393},{"nctId":"NCT02238080","phase":"","title":"An Observational Study of Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) in Chronic Kidney Disease Participants on Dialysis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-12","conditions":"Chronic Kidney Diseases","enrollment":197},{"nctId":"NCT01194154","phase":"PHASE2","title":"A Study of Methoxy Polyethylene Glycol-epoetin Beta (Mircera) in Participants With Chronic Kidney Disease (PRIMAVERA)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-09-30","conditions":"Kidney Disease, Chronic","enrollment":241},{"nctId":"NCT00394953","phase":"PHASE3","title":"A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-12","conditions":"Anemia","enrollment":490},{"nctId":"NCT00077610","phase":"PHASE3","title":"A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-02","conditions":"Anemia","enrollment":673},{"nctId":"NCT00364832","phase":"PHASE2","title":"A Study of Subcutaneous (sc) Mircera in Dialysis Patients With Chronic Renal Anemia.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2001-10","conditions":"Anemia","enrollment":137},{"nctId":"NCT00048035","phase":"PHASE2","title":"A Study of Intravenous (iv) Mircera in Hemodialysis Patients With Chronic Renal Anemia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2002-03","conditions":"Anemia","enrollment":91},{"nctId":"NCT00576628","phase":"PHASE3","title":"A Study of Subcutaneous C.E.R.A. for the Treatment of Anemia in Pre-Dialysis Patients.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-05","conditions":"Anemia","enrollment":133},{"nctId":"NCT00576602","phase":"PHASE4","title":"A Study of Subcutaneous Mircera, Versus no Erythropoiesis-Stimulating Agent (ESA) Therapy, in the Treatment of Anemia in Patients With Chronic Kidney Disease After Kidney Transplant","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2007-12","conditions":"Anemia","enrollment":1},{"nctId":"NCT01309295","phase":"","title":"An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Patients With Chronic Kidney Disease in Pre-Dialysis or Dialysis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-11","conditions":"Anemia, Kidney Disease, Chronic","enrollment":250},{"nctId":"NCT00081471","phase":"PHASE3","title":"A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-06","conditions":"Anemia","enrollment":324},{"nctId":"NCT00077597","phase":"PHASE3","title":"A Study of Mircera for the Treatment of Anemia in Dialysis Patients","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-02","conditions":"Anemia","enrollment":182},{"nctId":"NCT01309269","phase":"","title":"Observational Study to Investigate the Long-term Effects of MIRCERA in Clinical Routine","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-09","conditions":"Anemia","enrollment":1083},{"nctId":"NCT00081484","phase":"PHASE3","title":"A Study of Intravenous or Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-06","conditions":"Anemia","enrollment":336},{"nctId":"NCT00773331","phase":"PHASE3","title":"A Study Comparing Maintenance of Hemoglobin Levels, Safety and Tolerability of Once Every 4 Weeks Mircera Versus Epoetin Beta in Dialysis Patients With Chronic Renal Anemia.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-07","conditions":"Anemia","enrollment":281},{"nctId":"NCT00922610","phase":"PHASE4","title":"A Study of Mircera in Renal Anemia Among Filipino Chronic Kidney Disease Patients","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-02","conditions":"Anemia","enrollment":28},{"nctId":"NCT00442793","phase":"PHASE3","title":"A Study Comparing Mircera and Epoetin Beta for the Treatment of Anemia in Dialysis Patients With Chronic Kidney Disease.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-05","conditions":"Anemia","enrollment":265},{"nctId":"NCT01974271","phase":"","title":"An Observational Study of Hemoglobin Stability in Chronic Kidney Disease Patients on Dialysis Treated With Mircera (Methoxy Polyethylene Glycol-epoetin Beta)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-01","conditions":"Anemia","enrollment":661},{"nctId":"NCT01690455","phase":"","title":"An Observational Study of Mircera in Renal Anemia Correction In Dialysed Patients During Daily Clinical Practice","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-07","conditions":"Anemia","enrollment":247},{"nctId":"NCT01667380","phase":"","title":"An Observational Study of Mircera in Patients With Chronic Renal Anemia on Dialysis (CKD Stage V) or Not on Dialysis (CKD Stage III-IV)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2012-04","conditions":"Anemia","enrollment":78},{"nctId":"NCT01213485","phase":"","title":"An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Patients With Chronic Kidney Disease on Dialysis (HORTENSIA)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-03","conditions":"Anemia","enrollment":419},{"nctId":"NCT00559273","phase":"PHASE3","title":"A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Participants With Chronic Kidney Disease Not on Dialysis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-12","conditions":"Renal Anemia, Chronic","enrollment":307},{"nctId":"NCT01892202","phase":"","title":"A Non-Interventional Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Patients With Chronic Kidney Disease Not on Dialysis","status":"NO_LONGER_AVAILABLE","sponsor":"Hoffmann-La Roche","startDate":"2011-02","conditions":"Anemia","enrollment":""},{"nctId":"NCT00077766","phase":"PHASE3","title":"A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-03","conditions":"Anemia","enrollment":313},{"nctId":"NCT00882713","phase":"PHASE3","title":"A Study of Once Monthly Subcutaneous Mircera in Dialysis Patients With Chronic Renal Anemia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-02","conditions":"Anemia","enrollment":202},{"nctId":"NCT00605345","phase":"PHASE3","title":"A Study Comparing Subcutaneous Mircera and Darbepoetin Alfa for Maintenance Treatment of Anemia in Kidney Transplant Recipients.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-12","conditions":"Anemia","enrollment":71},{"nctId":"NCT00546481","phase":"PHASE3","title":"A Study of Intravenous Mircera for the Correction of Anemia in Dialysis Patients.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-11","conditions":"Anemia","enrollment":80},{"nctId":"NCT02263833","phase":"","title":"An Observational, Prospective, Safety Study of Mircera (Monopegylated Epoetin Beta) in Clinical Practice","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-09","conditions":"Kidney Disease, Chronic","enrollment":748},{"nctId":"NCT00560547","phase":"PHASE3","title":"A Study of Once-Monthly Intravenous Mircera in Hemodialysis Patients With Chronic Renal Anemia.","status":"WITHDRAWN","sponsor":"Hoffmann-La Roche","startDate":"2007-10","conditions":"Anemia","enrollment":""},{"nctId":"NCT00442416","phase":"PHASE3","title":"A Study of Subcutaneous Mircera for the Treatment of Anemia in Peritoneal Dialysis Patients.","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2007-02","conditions":"Anemia","enrollment":80},{"nctId":"NCT00327535","phase":"PHASE2","title":"A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving First Line Chemotherapy.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-05","conditions":"Anemia","enrollment":153},{"nctId":"NCT00545571","phase":"PHASE3","title":"MIRACLE Study: A Study of Once-Monthly Intravenous Mircera in Hemodialysis Participants With Chronic Renal Anemia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-10","conditions":"Anemia","enrollment":120},{"nctId":"NCT00642850","phase":"PHASE3","title":"STABIL Study: National Study With Mircera for Maintenance of Hemoglobin Level in Dialysis Patients","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-11","conditions":"Anemia","enrollment":188},{"nctId":"NCT01695746","phase":"","title":"An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Stage III-IV Chronic Kidney Disease Patients Not on Dialysis With Renal Anemia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-08","conditions":"Anemia","enrollment":108},{"nctId":"NCT00737711","phase":"PHASE4","title":"A Study of Two-Weekly Intravenous Mircera for the Treatment of Dialysis Patients With Chronic Renal Anemia Not Receiving ESA Therapy.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-07","conditions":"Anemia","enrollment":189},{"nctId":"NCT00517881","phase":"PHASE3","title":"Efficacy, Safety and Tolerability Study of Subcutaneous C.E.R.A. in Pre-Dialysis Participants With Chronic Renal Anemia","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2007-06","conditions":"Anemia","enrollment":29},{"nctId":"NCT00576303","phase":"PHASE3","title":"A Study of Intravenous Mircera in Dialysis Patients With Chronic Renal Disease and Anemia.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-04","conditions":"Anemia","enrollment":200},{"nctId":"NCT00077623","phase":"PHASE3","title":"A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-03","conditions":"Anemia","enrollment":572},{"nctId":"NCT00605293","phase":"PHASE3","title":"A Study of Intravenous Mircera (C.E.R.A or Methoxy Polyethylene Glycol-epoetin Beta) for the Maintenance Treatment of Hemodialysis Participants With Chronic Renal Anemia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-01","conditions":"Anemia","enrollment":101},{"nctId":"NCT00517413","phase":"PHASE3","title":"LATINO Study: A Study of Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-10","conditions":"Anemia","enrollment":163},{"nctId":"NCT00699348","phase":"PHASE3","title":"A Study of Monthly Intravenous C.E.R.A. (Mircera) in Hemodialysis Participants With Chronic Renal Anemia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-07","conditions":"Anemia","enrollment":351},{"nctId":"NCT00559637","phase":"PHASE3","title":"A Study of Subcutaneous Mircera in Participants With Chronic Kidney Disease Not Treated With ESA or on Dialysis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-01","conditions":"Anemia","enrollment":184},{"nctId":"NCT00773968","phase":"PHASE3","title":"A Study of Monthly Subcutaneous Continuous Erythropoietin Receptor Activator (CERA) in Predialysis Participants With Chronic Renal Anemia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-09","conditions":"Anemia","enrollment":140},{"nctId":"NCT00462384","phase":"PHASE3","title":"A Study of Subcutaneous Mircera for the Treatment of Anemia in Pre-Dialysis Participants With Chronic Kidney Disease.","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2008-02","conditions":"Anemia","enrollment":39},{"nctId":"NCT00550680","phase":"PHASE3","title":"A Study of Mircera for the Maintenance Treatment of Participants With Chronic Renal Anemia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-01","conditions":"Chronic Renal Anemia","enrollment":208},{"nctId":"NCT01422824","phase":"","title":"An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) as Maintenance Treatment in Patients With Chronic Renal Anemia on Haemodialysis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-06","conditions":"Anemia, Kidney Disease, Chronic","enrollment":185},{"nctId":"NCT00660023","phase":"PHASE3","title":"A Study of Intravenous Mircera in Participants With Chronic Renal Anemia Who Are on Dialysis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-08","conditions":"Anemia","enrollment":124},{"nctId":"NCT00413894","phase":"PHASE3","title":"A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-03","conditions":"Anemia","enrollment":424},{"nctId":"NCT02540213","phase":"","title":"Observational Study of MIRCERA in Users of Self-Application and Multidose Systems","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-01","conditions":"Renal Anemia of Chronic Kidney Disease","enrollment":240},{"nctId":"NCT01051323","phase":"","title":"An Observational Study of Mircera (Methoxy Polyethylene Glycol-epoetin Beta) in Patients With Renal Anemia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-03","conditions":"Anemia","enrollment":1580}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":48,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Epoetin beta pegol","genericName":"Epoetin beta pegol","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Epoetin beta pegol is a pegylated erythropoietin analog that stimulates erythropoiesis by binding to and activating the erythropoietin receptor on bone marrow progenitor cells. Used for Anemia in patients with chronic kidney disease, Anemia in patients with cancer receiving chemotherapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}